Investing.com -- Deutsche Bank upgraded Gilead Sciences Inc (NASDAQ:GILD) to "Buy" from "Hold" and raised its price target to $120 from $80 on long-term revenue growth potential in the company’s core HIV treatment franchise.
The bank highlighted the upcoming 2025 launch of lenacapavir for pre-exposure prophylaxis (PrEP) as a key driver, forecasting $619 million in LEN sales for fiscal 2025 and $3.7 billion by 2035. The firm believes Gilead’s long-acting HIV treatments will help offset future patent expirations, sustaining revenue growth into the next decade.
Despite Gilead’s stock trading at a higher valuation than its historical average, Deutsche Bank (ETR:DBKGn) argues it remains attractive relative to biopharma peers with long-term growth prospects, such as Eli Lilly (NYSE:LLY) and Vertex Pharmaceuticals (NASDAQ:VRTX).
Shares of Gilead were trading up 2%.
Related Articles
Deutsche Bank upgrades Gilead on its HIV treatment franchise
Iraq-Kurdistan pipeline set to reopen
Salesforce: BofA says channel checks are positive
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。